JP2020522269A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522269A5
JP2020522269A5 JP2019567677A JP2019567677A JP2020522269A5 JP 2020522269 A5 JP2020522269 A5 JP 2020522269A5 JP 2019567677 A JP2019567677 A JP 2019567677A JP 2019567677 A JP2019567677 A JP 2019567677A JP 2020522269 A5 JP2020522269 A5 JP 2020522269A5
Authority
JP
Japan
Prior art keywords
nucleic acid
recombinant nucleic
binding site
mir
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036200 external-priority patent/WO2018226785A1/en
Publication of JP2020522269A publication Critical patent/JP2020522269A/ja
Publication of JP2020522269A5 publication Critical patent/JP2020522269A5/ja
Priority to JP2023135189A priority Critical patent/JP2023164447A/ja
Pending legal-status Critical Current

Links

JP2019567677A 2017-06-06 2018-06-06 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター Pending JP2020522269A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023135189A JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516060P 2017-06-06 2017-06-06
US62/516,060 2017-06-06
PCT/US2018/036200 WO2018226785A1 (en) 2017-06-06 2018-06-06 Self-regulating aav vectors for safe expression of mecp2 in rett syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135189A Division JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Publications (2)

Publication Number Publication Date
JP2020522269A JP2020522269A (ja) 2020-07-30
JP2020522269A5 true JP2020522269A5 (enExample) 2021-07-26

Family

ID=64567243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567677A Pending JP2020522269A (ja) 2017-06-06 2018-06-06 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Country Status (15)

Country Link
US (2) US11680275B2 (enExample)
EP (1) EP3635122A4 (enExample)
JP (2) JP2020522269A (enExample)
KR (1) KR20200015701A (enExample)
CN (1) CN111065742A (enExample)
AU (1) AU2018281145A1 (enExample)
BR (1) BR112019025732A2 (enExample)
CA (1) CA3066623A1 (enExample)
CL (1) CL2019003582A1 (enExample)
CO (1) CO2019014840A2 (enExample)
EA (1) EA201992882A1 (enExample)
IL (1) IL271170A (enExample)
MX (1) MX2019014760A (enExample)
SG (1) SG11201911737PA (enExample)
WO (1) WO2018226785A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
CA3044291A1 (en) * 2016-11-17 2018-05-24 Nationwide Children's Hospital Inc. Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
WO2018138371A1 (en) 2017-01-30 2018-08-02 Brainvectis Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
CN112272672A (zh) 2018-04-03 2021-01-26 斯特里迪比奥公司 抗体逃避性病毒载体
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ,インコーポレイテッド 抗体を回避するウイルスベクター
KR20210006358A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 안 조직을 표적으로 하기 위한 바이러스 벡터
CA3115217A1 (en) 2018-10-02 2020-04-09 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
EP3973060A4 (en) * 2019-04-24 2023-05-10 The Trustees of The University of Pennsylvania COMPOSITIONS USEFUL FOR THE TREATMENT OF RETT SYNDROME
US20220233654A1 (en) * 2019-05-21 2022-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
WO2021113634A1 (en) * 2019-12-05 2021-06-10 The Board Of Regents Of The University Of Texas Transgene cassettes designed to express a human mecp2 gene
EP4117735A4 (en) * 2020-03-09 2024-04-10 University of Massachusetts Gene replacement therapy for foxg1 syndrome
MX2022014256A (es) * 2020-05-13 2023-01-11 Voyager Therapeutics Inc Redirección del tropismo de las cápsides de aav.
US20230323391A1 (en) * 2020-06-30 2023-10-12 The University Court Of The University Of Edinburgh Transgene expression system
IL300728A (en) * 2020-08-19 2023-04-01 Sarepta Therapeutics Inc Adeno-associated virus vectors for the treatment of Rett syndrome
CN113717248B (zh) * 2020-09-30 2022-07-08 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
TW202334436A (zh) 2021-11-02 2023-09-01 美商航海家醫療公司 Aav衣殼變異體及其用途
GB202201242D0 (en) * 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
WO2024194491A1 (en) * 2023-03-22 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
CN121175427A (zh) * 2023-05-15 2025-12-19 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗
CN119101681A (zh) * 2023-06-09 2024-12-10 仁景(苏州)生物科技有限公司 表达可调控的工程化rna分子

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
BR122016004546B8 (pt) 2001-11-13 2021-07-27 Univ Pennsylvania vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
BRPI0817812A2 (pt) 2007-10-23 2015-04-14 Novartis Ag Uso de anticorpos trkb para o tratamento de distúrbios respiratórios
TW200936608A (en) 2008-01-17 2009-09-01 Irm Llc Improved anti-TrkB antibodies
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
EA201390616A1 (ru) 2010-10-25 2013-09-30 Юниверсите Д'Экс-Марсель ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
US20160000794A1 (en) 2012-09-25 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods for the diagnosis and treatment of sjogren's syndrome
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
JP6842410B2 (ja) 2014-10-03 2021-03-17 ユニバーシティ オブ マサチューセッツ 新規の高効率ライブラリーにより同定されるaavベクター
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
JP7023108B2 (ja) 2014-10-21 2022-02-21 ユニバーシティ オブ マサチューセッツ 組み換えaavバリアントおよびその使用
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
EP3121284A1 (en) * 2015-07-22 2017-01-25 Ecole Polytechnique Fédérale de Lausanne (EPFL) Bicistronic aav vector for rna interference in als

Similar Documents

Publication Publication Date Title
JP2020522269A5 (enExample)
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2021106619A5 (enExample)
US20220331409A1 (en) Factor ix gene therapy
JP6619454B2 (ja) キャプシド
JP2024009857A5 (enExample)
JP2018522529A5 (enExample)
JP2007507223A5 (enExample)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2018531609A5 (enExample)
TW202005978A (zh) 新穎肝靶向腺相關病毒載體
JP2017509632A5 (enExample)
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
JP2017529395A5 (enExample)
JP2020519284A5 (enExample)
JP2020519294A5 (enExample)
FI3177313T3 (fi) Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi
JPWO2021222168A5 (enExample)
JPWO2021221995A5 (enExample)
JP2020533313A5 (enExample)
RU2021132081A (ru) Векторы фактора h и их применения
JPWO2022028472A5 (enExample)
RU2022111695A (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение
JPWO2021248038A5 (enExample)
JPWO2020210480A5 (enExample)